小池 直義 (コイケ ナオヨシ)

Koike, Naoyoshi

写真a

所属(所属キャンパス)

医学部 放射線科学教室(治療) (信濃町)

職名

助教(有期)

外部リンク

経歴 【 表示 / 非表示

  • 2005年04月
    -
    2007年03月

    静岡赤十字病院, 院研修医

  • 2007年04月
    -
    2009年03月

    慶應義塾大学病院, 放射線科, 専修医

  • 2009年04月
    -
    2011年01月

    川崎市立川崎病院, 放射線治療科, 医師

  • 2011年02月
    -
    2011年03月

    独立行政法人東京医療センター, 放射線科, レジデント

  • 2011年04月
    -
    2012年03月

    独立行政法人東京医療センター, 放射線科, 医員

全件表示 >>

学歴 【 表示 / 非表示

  • 1999年04月
    -
    2005年03月

    慶應義塾, 医学部

    大学, 卒業

  • 2013年04月
    -
    2017年03月

    慶應義塾, 医学部

    大学院, 単位取得退学, 博士

免許・資格 【 表示 / 非表示

  • 医師免許, 2005年

  • 放射線治療専門医, 2011年09月

  • がん治療認定医, 2013年04月

 

研究分野 【 表示 / 非表示

  • 放射線科学

研究キーワード 【 表示 / 非表示

  • がん幹細胞

  • 低酸素

  • 脳腫瘍

 

論文 【 表示 / 非表示

  • Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival

    Ito K., Saito S., Yorozu A., Kojima S., Kikuchi T., Higashide S., Aoki M., Koga H., Satoh T., Ohashi T., Nakamura K., Katayama N., Tanaka N., Nakano M., Shigematsu N., Dokiya T., Fukushima M., Takahashi Y., Tsukiyama I., Nasu Y., Harada M., Fukagai T., Yamashita T., Matsubara A., Igawa M., Egawa S., Kakehi Y., Katsuoka Y., Kanetake H., Kubota Y., Kumon H., Yamasaki I., Suzuki K., Deguchi T., Ueno M., Naito S., Namiki M., Baba S., Hayakawa K., Hirao Y., Fujioka T., Horie S., Miki T., Murai M., Yoshida H., Itami J., Inoue T., Imai Y., Kataoka M., Kubo A., Shibuya H., Nishio M., Tanaka H., Tanaka Y., Teramukai S., Harada C., Yamashiro K., Kiba T., Kitagawa S., Uno E., Nishimura T., Kinoshita F., Iida S., Maruo S., Miyakoda K., Daimon T., Kawamoto A., Kaneda H., Yoshidomi M., Nishiyama T., Yagi Y., Namitome R., Toya K., Koike N., Yoshida K., Tabata K., Tsumura H., Kimura M., Ishiyama H., Kotani S., Kondo H., Fujimoto K., Hasegawa M., Tamamoto T., Asakawa I., Nishizawa S., Hashida I., Takezawa Y., Harada K., Tanji S., Sato K., Matsuura T., Ariga H., Ehara S., Nakamura R., Hayashi S., Ohtakara K., Kihara K., Hayashi K., Okamoto K.

    International Journal of Clinical Oncology (International Journal of Clinical Oncology)  23 ( 6 ) 1148 - 1159 2018年12月

    ISSN  13419625

     概要を見る

    © 2018, Japan Society of Clinical Oncology. Background: Investigating oncological outcomes in patients registered in the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) in terms of biochemical relapse-free survival (bRFS) by the Phoenix and the newly developed J-POPS definitions, exploration of predictive factors for bRFS, and preliminary verification of pitfalls of prostate-specific antigen (PSA) failure definitions. Methods: Between July 2005 and June 2007, 2316 clinically localized patients underwent permanent seed implantation. The primary endpoint was bRFS. One of the secondary endpoints was overall survival (OS). Results: The median age was 69 and performance status was 0 in 99.1% of participants. The median biologically effective dose (BED) was about 180 Gy 2 . During a median follow-up of 60.0 months, 8.4 and 5.9% had PSA failure by the Phoenix and the J-POPS definitions, respectively. The 5-year bRFSs based on the Phoenix and the J-POPS definitions were 89.1 and 91.6%, respectively. The 5-year OS was 97.3%. According to multivariate analyses, only age affected bRFS based on the Phoenix definition, whereas the risk group and BED independently affected bRFS based on the J-POPS definition. A spontaneous PSA decrease was seen in 91.1% of participants after PSA failure based on the Phoenix definition alone, but in only 22.2% after PSA failure based on the J-POPS definition alone. Conclusion: The world’s largest registration study, J-POPS, consisted of patients with longevity, and a highly quality-controlled BED resulted in excellent bRFS and OS. The high likelihood of PSA bounce by the Phoenix definition should be taken into account, especially in younger patients. Clinical trial information: NCT00534196.

  • Influence of backscatter radiation on cranial bone fixation devices

    Sakamoto Y., Koike N., Takei H., Ohno M., Shigematsu N., Kishi K.

    Journal of Craniofacial Surgery (Journal of Craniofacial Surgery)  29 ( 4 ) 1094 - 1096 2018年06月

    ISSN  10492275

     概要を見る

    © 2018 by Mutaz B. Habal, MD. Postoperative radiation can cause ulcer formation, leading to the denudation of skin over alloplastic materials. The influence of backscatter radiation from fixation devices has not been investigated. The aim of this study is to evaluate backscatter dose variations for different cranial bone fixation devices in an experimental model designed to simulate postoperative radiotherapy. The authors assessed the radiation backscatter doses associated with resorbable (PLLA-PGA) and titanium plates. The samples were irradiated with 6 and 10 MV photon beams from a linear accelerator. Measurements were obtained using an ionization chamber and radiochromic films cut from the same batch. As a result, the backscatter radiation of water and PLLA-PGA proportionally decreased as the depth increased. However, the backscatter radiation of the titanium plate increased just above the plate. This depth lies in the region of the scalp. Each material showed a dose of radioactivity that was higher at 10 MV than that at 6 MV. These devices showed a significant difference, which suggested that these materials amplified the dose compared with water at 6 MV. In conclusion, it is supposed that PLLA-PGA should be used to fix the cranium to decrease the potential for radiation ulcers.

  • Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma

    Kumabe A., Fukada J., Kota R., Koike N., Shiraishi Y., Seki S., Yoshida K., Kitagawa Y., Shigematsu N.

    Diseases of the Esophagus (Diseases of the Esophagus)  31 ( 4 )  2018年04月

    ISSN  1120-8694

     概要を見る

    © The Author(s) 2017. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. We investigated long-term treatment outcomes and the feasibility of chemoradiotherapy consisting of daily-low-dose 5-fluorouracil and cisplatin (LDFP) chemotherapy plus radiotherapy for Stage I-II squamous cell esophageal cancer. Treatment records from the 2000 through 2008 period were reviewed retrospectively. Fractionated radiotherapy was performed with a total dose of 60 Gy delivered in 2 Gy per fraction. LDFP chemotherapy, as continuous infusion of 200 mg/m 2 5-fluorouracil combined with one hour infusion of 4 mg/m 2 cisplatin, was administered on the same days as radiotherapy. Survival was calculated by the Kaplan-Meier method. Survival, responses, failure patterns, and toxicities were evaluated. Seventy-six (47 stage I and 29 stage II) patients were analyzed with a median follow-up of 93.6 months. The 8-year overall survival (OS), progression-free survival (PFS) and cause-specific survival (CSS) rates were 63.4%, 49.8%, and 76.7%, respectively. The 8-year OS, PFS, and CSS for stage I and stage II patients were 71.0%/56.1%/82.9% and 45.2%/40.2%/66.6%, respectively. Sixty-eight patients (89.5%) completed the treatment regimen. A complete response (CR) was achieved in 68 patients (89.5%). Twenty-five patients (36.8%) experienced recurrence after CR. The failure patterns were (overlap included): local failure (n = 12), nodal metastasis (n = 12), distant metastasis (n = 3), details unknown (n = 2). Salvage therapy was performed for local failure; endoscopic therapy (n = 7) or surgery (n = 2). Six patients remain alive without relapse after salvage endoscopic therapy. Major Grade 3 or higher acute adverse events were leukopenia (22%), anorexia (17%), and esophagitis (11%). Major late toxicities (Grade 3 or 4) involved pericardial effusion (12%), pleural effusion (4%), and esophageal stenosis (3%). Chemoradiotherapy with LDFP provided favorable long-term survival with acceptable toxicity for Stage I-II squamous cell esophageal cancer. The tumor response was excellent, but close endoscopic follow-up is essential for detecting and treating local recurrence.

  • Metabolic heterogeneity and plasticity of glioma stem cells in a mouse glioblastoma model

    Shibao S., Minami N., Koike N., Fukui N., Yoshida K., Saya H., Sampetrean O.

    Neuro-Oncology (Neuro-Oncology)  20 ( 3 ) 343 - 354 2018年02月

    ISSN  1522-8517

     概要を見る

    © 2018 The Author(s). Background. Glioblastomas have been shown to rely on glycolysis as an energy source. However, recent evidence suggests that at least a subset of glioma cells with stem cell-like properties can thrive on oxidative phosphorylation. It remains unclear whether both metabolic phenotypes support tumor propagation, if they are independent, and how stable they are. The present study investigated these questions with the use of isogenic murine glioma stem cells (GSCs). Methods. GSCs were established from tumors formed by Ink4a/Arf-null, H-RasV12-expressing glioma-initiating cells that differed in extracellular acidification potential. Metabolic characteristics of GSCs were determined by measurement of glucose, oxygen, and glutamine uptake, ATP content, and lactate production. Effects of metabolic inhibitors and changes in oxygen or nutrient availability on lactate production and tumorsphere growth were also determined. Results. GSCs were found either to consume more glucose and produce more lactate or to consume more oxygen and maintain a higher ATP content depending on the metabolic characteristics of the tumor cells of origin. The latter, mitochondrial-type GSCs increased lactate production after treatment with the oxidative phosphorylation inhibitor oligomycin or phenformin. Exposure to hypoxia also increased lactate production and expression of glycolysis-related enzymes and metabolites in mitochondrial-type GSCs in a reversible manner. Conclusions. Both glycolytic and mitochondrial-type energy production can sustain tumor propagation by isogenic GSCs. Whereas both phenotypes can be independent and stable, cells that rely on oxidative phosphorylation can also switch to a more glycolytic phenotype in response to metabolic stress, suggesting that plasticity is a further characteristic of GSC metabolism.

  • Influence of backscatter radiation on cranial reconstruction implants

    Sakamoto Yoshiaki, Koike Naoyoshi, Takei Hideyuki, Ohno Mari, Miwa Tomoru, Yoshida Kazunari, Shigematsu Naoyuki, Kishi Kazuo

    British Journal of Radiology 90 ( 1070 )  2017年

    共著, 査読有り,  ISSN  0007-1285

     概要を見る

    <p>Objective: We aimed to evaluate backscatter dose variations in different cranial bone implant materials in an experimental model designed to simulate postoperative radiotherapy. Methods: We assessed the radiation backscatter doses associated with sheet- and mesh-type titanium plates and hydroxyapatite (HAP) samples (porosity: 35%, 50% and 85%). The samples were irradiated with 6- and 10-MV photon beams from a linear accelerator. Measurements were obtained using an ionization chamber and radiochromic films cut from the same batch. Results: At 6MV, the titanium sheet showed the highest peak for backscattered radiation, followed by (in decreasing order) HAP30%, HAP50%, titanium mesh and HAP85%. At 10MV, HAP30% showed the highest peak, followed by HAP50%, titanium sheet, titanium mesh and HAP85%. The peaks were at different depths in the titanium and HAP samples. The thickness of the human scalp is approximately 7mm; therefore, measurements were obtained 0-7mm above the implants to assess the likely dose on the scalp. A comparison of the maximum dose on the scalp showed the titanium sheet had the highest dose at both 6 and 10MV. Conclusion: The backscatter dose differed with the density of the material and the backscatter depth was different for each material. Advances in knowledge: Ulcer formation due to radiotherapy after brain tumour depends on not only radiation but also the implant material. Therefore, the density and type of implant material should be considered when planning radiotherapy and selecting bone reconstruction materials.</p>

全件表示 >>

研究発表 【 表示 / 非表示

  • マウス膠芽腫モデルにおける低酸素放射線増感剤ドラニダゾールの効果

    小池 直義

    日本放射線腫瘍学会第30回学術大会, 2017年11月, 口頭(一般)

  • グリオーマ幹細胞の放射線抵抗性におけるネスチンの役割の解析

    小池 直義

    日本放射線腫瘍学会第29回学術大会, 2016年11月, 口頭(一般)

  • 放射線によって誘導されるグリオーマ幹細胞の細胞外小胞の解析

    小池 直義

    第33回日本脳腫瘍学会学術集会, 2015年12月, ポスター(一般)

  • Cell cycle imaging in irradiated murine glioma stem cells.

    小池 直義

    International Symposium on Multi-dimensional Fluorescence Live Imaging of Cellular Functions and Molecular Activities, 2015年01月, ポスター(一般)

  • サイバーナイフによる肝腫瘍呼吸性移動追尾照射における腫瘍と金マーカーの呼吸性移動の違い.

    小池 直義

    第73回日本医学放射線学会総会, 2014年04月, 口頭(一般)

全件表示 >>

競争的資金等の研究課題 【 表示 / 非表示

  • 膠芽腫の低酸素領域克服に向けた薬剤の同定と解析

    2018年04月
    -
    2020年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 小池 直義, 若手研究, 補助金,  代表